The Study of Qishenyiqi Drop Pills in Improving the Prognosis of Heart Failure Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 5380 participants.

Also called NCT04028544

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 5,380 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04028544
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04028544. Randomized; quadruple masking; primary purpose treatment. Start 2019-03-26 (actual); primary completion 2020-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Study of Qishenyiqi Drop Pills in Improving the Prognosis of Heart Failure Patients
Condition
Heart Failure
Intervention (Drug)
Qishenyiqi dropping pills
Intervention (Drug)
Placebo
Lead sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital (class: other)
Collaborator
Tianjin Tasly Pharmaceutical Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct04028544
Content hash
a86e4379eaa2235f248c0f38f2af16c2d310ae102a6660dcf442bca297d57c47